The Annual Report, which is attached in Swedish, can also be downloaded from the company's Swedish website (https://www.bioarctic.se/sv/finansiella-rapporter-2557/). An English translation of the Annual Report is estimated to become available on the website on April 14, 2022.

---

For further information, please contact:

Jan Mattsson, CFO,

E-mail: jan.mattsson@bioarctic.se

Phone: + 46 70352 27 72

Oskar Bosson, Vice President Communications and Investor Relations
E-mail:oskar.bosson@bioarctic.se
Phone: +46 70 410 71 80

This information is information that BioArctic AB (publ) is obliged to make public pursuant to the Swedish Securities Market Act. The information was submitted for publication at 08:00 am CET on March 31, 2022.

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. BioArctic's Class B share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com (http://www.bioarctic.come).